ZyVersa Therapeutics, Inc. (ZVSA) Form 10-Q — May 13, 2026
ZyVersa Therapeutics, Inc. reported a net loss of $1.8 million for the three months ended March 31, 2026, compared to a net loss of $2.3 million for the same period in 2025. The decrease in net loss is primarily due to lower research and development and general and administrative expenses. The company's cash position as of March 31, 2026, was $302,660, a significant increase from $101,778 at the end of 2025.
Key figures
- Eps
- -0.22
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -1,793,381
- Total Debt
- 1,200,000
- Debt Amount
- 1,200,000
- Revenue Yoy
- 0
- Total Assets
- 742,223
- Cash Position
- 302,660
- Deal Value Usd
- 0
- Interest Rate
- 10%
- Maturity Date
- February 27, 2027
- Gross Proceeds
- 1,000,000
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 8,095,928
- Working Capital Deficiency
- -14,124,295
Price after filing
1 day: +11.0%7 days: +0.1%30 days: +8.3%
Close on the filing date to close N calendar days later (from $0.18). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.